NetScientific Plc (LON:NSCI) told investors that its portfolio company ProAxsis will present data on its ProteaseTag technology at the American Thoracic Society (ATS) Conference.
The conference takes place in Washington DC, between May 19 and May 24.
CLICK HERE: For a daily round-up of all the Proactive news
ProAxsis, which is developing products to detect protease disease biomarkers, has submitted to ATS abstracts for data relating to three products being developed by ProAxsis in chronic diseases including COPD, bronchiectasis and Cystic Fibrosis.
"The broad range of major disease indications covered in these studies demonstrates the versatility of the ProteaseTag technology being developed by ProAxsis,” said François R. Martelet, NetScientific chief executive.
“We look forward to the continued development of these exciting products and expect to see them commercially available by the end of 2017."